Novavax Trivalent vaccine

The Novavax Trivalent vaccine refers to a protein-based, adjuvanted trivalent (three-component) vaccine candidate developed by Novavax. While the specific formulation and target antigens of the "Novavax Trivalent vaccine" are not explicitly detailed in the provided sources, Novavax is known for developing advanced recombinant nanoparticle vaccines using its proprietary Matrix-M adjuvant technology. The company has multiple trivalent and combination vaccines in development, including stand-alone influenza vaccines and COVID-influenza combination candidates that utilize three or more viral antigens to induce broad immune responses[10]. These vaccines work by presenting recombinant viral proteins (such as spike proteins from SARS-CoV-2 or hemagglutinin from influenza viruses) along with Matrix-M adjuvant to stimulate both humoral and cellular immunity. The primary indications for these trivalent formulations are prevention of respiratory viral infections such as COVID-19 and seasonal influenza.